Skip to main content

Gelatin Capsule Market: Global Growth Trends & Forecast

Page 1

01 — Market Intelligence Brief

Global Gelatin Capsule Market Sizing, segmenting and stress-testing the next five years of oral oral dosage delivery. 2024 Market Size

2030 Projection

$5.85B

$8.08B

Anchor year · Next Move intelligence base

Forecast · patient + supplement demand

Reference · Oral dosage

5.5%

Five-year CAGR, 2025 → 2030

$5.85B

$8.08B

How the market is segmented

By Type

By Raw Material

By Application

By Region

Hard Soft

Bovine Porcine · Other

Pharmaceutical Nutraceutical

Europe · N. America Asia-Pacific · RoW

Executive Summary

The market is in a steady compounding phase: pharma spend rises, formulation flexibility widens, and Asia-Pacific pulls demand — while plantplant-based innovation opens a parallel track.

15

Companies profiled across the value chain

28

Countries covered across four regions

© 2024 Next Move Strategy Consulting · All rights reserved.

Source · Next MSC Gelatin Capsule Market Report, 2024


Growth Drivers & Opportunities

Where demand compounds through 2030. Reference · Variants

Five structural forces are pulling the category forward — and four Demand Drivers regions are absorbing the demand at very different speeds.

$40B

+8.4%

China nutraceutical market, 2023

Pharma prescription spend uplift, U.S.

Formulation flexibility

International Trade Administration: +14% yearCMS data shows U.S. Rx spend climbed to USD

on-year, fueling supplement demand for

Capsules carry powders, granules, liquids and select

USD 405.9B in 2022, up from 6.8% growth in

capsule formats.

semi-solids — broadening therapeutic surface area.

growth in 2021. Powder

Granule

Innovation Pipeline

High-Growth Segment

Plant-based and TiO₂-free platforms

India pharmaceutical expansion

Lonza introduced TiO₂-free hard capsules in May 2022 using crystalline-

USD 130B

crystalline-salt opacifiers; IFF launched Verdigel SC pectin premix in April

Liquid

Semi-solid

60%

premix in April 2023.

Regional Opportunities

Where the next leg of growth is loaded. loaded. 01 · Dominant

02 · Rising

03 · Mature

04 · Emerging

Europe

Asia-Pacific Pacific

North America

Rest of the World

Holds the dominant share; plantplant-based alternatives accelerating (~150M Europeans Europeans with allergies).

Pharma + nutraceutical surge: China $40B nutraceuticals, India $130B pharma target by 2030.

Rx drug spend growing at +8.4% in 2022; established supplement consumer base.

PRIMARY MARKET

FASTEST LANE

© 2024 Next Move Strategy Consulting · All rights reserved.

STEADY CURRENT

LATAM, MENA, Africa — early-stage but unlocks; local manufacturing partnerships emerging.

WATCH

Source · CMS, ITA, WHO, Indian Pharmaceutical Association


Competitive Scenario

Strategic posture across 15 profiled companies. A mid-fragmented field where innovation, M&A and CDMO partnerships are setting the setting the leaders apart. Leading companies

Share disclosed · 10 of 15

Tier-1

ACG

Tier-1

Lonza

Tier-1

Qualicaps

Global CDMO; ComboCap acquisition acquisition in Mar 2023

TiO₂-free hard gelatin capsules (May 2022)

Hard and soft gelatin across pharma + pharma + nutraceutical

HBI Eurocaps

Nectar Lifesciences Lifesciences

Sunil Healthcare

Tier-2

(DCC plc Group) · diversified capacity capacity

Tier-2

Tier-2

Innovator

+7 more

Long tail

Caps Canada · EMBOCAPS · Erawat · Dah Dah Feng · Fortcaps · GoCaps · Empty Capsules

Empty capsules + healthcare formulations

India-based; pharma-focused gelatin gelatin

GELITA AG

Strategic positioning

Innovation intensity × Scale Where capital is moving Specialists

Leader Quadrant

GLT

LZA

ACG

I n n o v a ti o n ↑

QCP

01 · Innovation Plant-based, TiO₂-free, easy-seal technologies. Verdigel SC, ComboCap 2-in-1 caps.

02 · M&A & Alliances ACG Vantage Nutrition acquired ComboCap; CDMOs announcing announcing specialty soft-gel launches at CPHI Barcelona. Barcelona.

03 · Geographic expansion Niche

High-Volume

Scale →

© 2024 Next Move Strategy Consulting · All rights reserved.

Source · Next MSC company profiles + disclosed announcements


Strategic Outlook

Four capital implications for the next 36 months. The shape of the opportunity, the seams where incumbents are vulnerable, and where disciplined capital can compound.

Implication 01

01

Implication 02

02

Capacity closer to Asia-Pacific demand demand

Premiumize through plant-based TiO₂-free, vegan and pectin-based capsules command a premium wedge in Europe, where ~150M residents live with allergies. PRICING · MARGIN EXPANSION

Implication 03

CAPEX · REGIONAL FOOTPRINT

03

Watchlist · Risk

!

Consolidate the long tail

Allergen & substitution drag

15 companies profiled, 10 with disclosed share — mid-fragmented. ACG's

Animal-sourced gelatin triggers skin and respiratory reactions; plant-based

ComboCap deal signals roll-up potential in specialty formats.

cost differential persists; drug-device convergence remains a long-tail risk.

M&A · ROLL-UP THESIS

DILIGENCE PRIORITY

Forward Signal · 36-Month Horizon Map

What to track, when to lean in.

0–12

Capacity, TiO₂-free and CDMO partnerships

months

Watch for new plant-based premixes and tier-1 expansion in Asia.

12–24 24 months

24–36

Specialty formulations + M&A roll-up 2-in-1 caps, soft-gel for menopause / eye health, niche consolidation.

Active-ingredient shells + platform plays Embed actives directly into shell; move from commodity to drug-delivery platform.

Build Near-term capex + product

Acquire Selective, capability-led

Reinvent Platform optionality

months

© 2026 Next Move Strategy Consulting · All rights reserved.

Compiled by Next MSC Strategy · Investor intelligence brief


Thank You

Let's continue the conversation. Website

nextmsc.com

Get the full report

nextmsc.com/report/ gelatin-capsule-market

Phone

+1 857-758-5017 Open the report → Email

info@nextmsc.com

Follow Us

Li

LinkedIn

Fb

Facebook

YT

YouTube

X

Twitter

Ig

Instagram


Turn static files into dynamic content formats.

Create a flipbook
Gelatin Capsule Market: Global Growth Trends & Forecast by him8899 - Issuu